Elizabeth Trehu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Elizabeth trehu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Elizabeth Trehu Today - Breaking & Trending Today

Maine must strengthen clean vehicle standards

Letter ....

United States , Elizabeth Trehu , Advanced Clean Cars ,

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Average Rating of "Buy" from Analysts

Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has been given an average rating of “Buy” by the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […] ....

Elizabeth Trehu , Life Insurance Co , Sumitomo Mitsui Financial Group , Macrophage Program , Invesco Ltd , Citigroup Inc , Royal Bank , Jounce Therapeutics Inc , Jounce Therapeutics , Get Rating , Mitsui Financial Group , Lead Macrophage Program , Macrophage Targeting , Nasdaq Jnce ,

Zacks: Analysts Anticipate Jounce Therapeutics, Inc. (NASDAQ:JNCE) to Post -$0.57 EPS

Wall Street analysts predict that Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) will report earnings per share (EPS) of ($0.57) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Jounce Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.62). Jounce Therapeutics posted earnings of ($0.58) per share […] ....

Elizabeth Trehu , Life Insurance Co , Sumitomo Mitsui Financial Group , Zacks Investment Research , Macrophage Program , Invesco Ltd , Citigroup Inc , Royal Bank , Jounce Therapeutics Inc , Wall Street , Jounce Therapeutics , Get Rating , Jounce Therapeutic , Mitsui Financial Group , Investment Research , Lead Macrophage Program , Macrophage Targeting , Nasdaq Jnce ,

Equities Analysts Set Expectations for Jounce Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:JNCE)

Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) – Research analysts at Piper Sandler cut their FY2022 earnings per share estimates for Jounce Therapeutics in a research note issued on Wednesday, March 2nd. Piper Sandler analyst E. Tenthoff now anticipates that the company will earn ($2.63) per share for the year, down from their prior estimate […] ....

United States , Elizabeth Trehu , Piper Sandler , Colony Group , Stifel Financial Corp , Zacks Investment Research , Deutsche Bank , Macrophage Program , Jounce Therapeutics Company Profile Get Rating , Jounce Therapeutics Inc , Jounce Therapeutics , Get Rating , Investment Research , Employees Retirement System , Therapeutics Company Profile , Lead Macrophage Program , Macrophage Targeting , Nasdaq Jnce , Earnings Estimates ,

Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript

JNCE earnings call for the period ending September 30, 2021. ....

Cory Kasimov , Tiffany Sun Jpmorgan , Raymond James , Ted Tenthoff Piper Sandler , Colleen Kusy Baird , Steven Seedhouse Raymond James , Dmitri Wiederschain , Steven Seedhouse , Richard Murray , Eric Laub , Beth Trehu , Kim Drapkin , Piper Sandler , Jigar Raythatha , Zegbeh Jallah , Colleen Kusy , Elizabeth Trehu , Swayampakula Ramakanth , Ted Tenthoff , Corporate Communications , Jounce Therapeutics , Jounce Therapeutic Third Quarter , Investor Relations , Vice President , Jounce Therapeutics Third Quarter , Private Securities Litigation ,